9
Apr
2025
What US Biotech Can Do to Meet the Moment
We have entered a new era in biotech. Turmoil at the FDA has introduced new uncertainty. NIH funding cuts and grant delays have led to academic institutions to hold off on job offers to young scientists. The Trump Administration’s reset of trade relations with the world caused a financial market meltdown, and wild rebound. All of these things are... Read More